Bio-Path Holdings, Inc. (NASDAQ:BPTH)’s share price hit a new 52-week low on Thursday . The company traded as low as $0.29 and last traded at $0.29, with a volume of 668,305 shares traded. The stock had previously closed at $0.34.
A number of equities analysts recently weighed in on BPTH shares. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Bio-Path Holdings in a research report on Tuesday, July 4th. Zacks Investment Research lowered shares of Bio-Path Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.
The company’s market capitalization is $27.79 million. The firm has a 50-day moving average price of $0.38 and a 200 day moving average price of $0.61.
Bio-Path Holdings (NASDAQ:BPTH) last announced its earnings results on Thursday, May 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.01. Equities research analysts expect that Bio-Path Holdings, Inc. will post ($0.07) EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in BPTH. Legal & General Group Plc raised its stake in shares of Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after buying an additional 1,741,978 shares during the period. Tower Research Capital LLC TRC purchased a new stake in Bio-Path Holdings during the first quarter worth $105,000. HighTower Advisors LLC raised its stake in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares during the last quarter. Sabby Management LLC raised its stake in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the last quarter. 19.90% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Bio-Path Holdings, Inc. (BPTH) Hits New 12-Month Low at $0.29” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2798785/bio-path-holdings-inc-bpth-hits-new-12-month-low-at-0-29.html.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.